New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Ascentage Pharma Group International - Unsponsored ADR (AAPG) vs Inhibrx Biosciences, Inc. (INBX)

Ascentage Pharma Group International - Unsponsored ADR and Inhibrx Biosciences, Inc. are both Biotechnology companies. Ascentage Pharma Group International - Unsponsored ADR and Inhibrx Biosciences, Inc. are of similar size ($1.2B and $1.1B). Across the 4 metrics below, Inhibrx Biosciences, Inc. leads on 4 and Ascentage Pharma Group International - Unsponsored ADR on 0.

Valuation

Metric AAPG INBX Biotechnology median
P/E — n/m 8.49
P/S — 309.73 8.56
P/B — n/m 2.04
Price to free cash flow — n/m 23.84
EV/EBITDA — n/m 0.69
EV/Sales — 331.80 8.00
Earnings yield — (13.14%) (35.81%)
Free cash flow yield — (12.24%) (25.41%)

Profitability

Metric AAPG INBX Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity — 577.65% (51.58%)
Return on assets — (71.23%) (45.91%)
Return on invested capital — 0.00% 0.00%

Growth

Metric AAPG INBX Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (177.78%) (108.03%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AAPG INBX Biotechnology median
Debt to equity 3.70 (3.22) 0.00
Current ratio 1.22 7.58 4.79
Net debt to EBITDA 0.44 0.18 1.01

Dividend

Metric AAPG INBX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AAPG INBX Biotechnology median
Market cap 1.16b 1.10b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack